Based onOncotype DX,a score of 35will receivethis treatmentUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agent canbe added toLN+ HER2+disease givenwithtrastuzumab1%Based onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis treatmentmodality isalwayscombined withlumpectomysurgeryThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThe onlysteroidalaromataseinhibitor in itsdrug classThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPreferredfrequencyof GnRHagonistsThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis agent cancauseendometrialcancer, but hasbone densityprotective effectPreferredregimen forHR+ diseasefor frail/elderlypatientsDuration of timepatients willtakeabemaciclib inearly stagediseaseThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This agentshould beinitiated withneratinib for thefirst 8 weeksThis drugclass are thebackbone ofHR+ diseaseI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearBased onOncotype DX,a score of 35will receivethis treatmentUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agent canbe added toLN+ HER2+disease givenwithtrastuzumab1%Based onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis treatmentmodality isalwayscombined withlumpectomysurgeryThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThe onlysteroidalaromataseinhibitor in itsdrug classThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPreferredfrequencyof GnRHagonistsThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis agent cancauseendometrialcancer, but hasbone densityprotective effectPreferredregimen forHR+ diseasefor frail/elderlypatientsDuration of timepatients willtakeabemaciclib inearly stagediseaseThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This agentshould beinitiated withneratinib for thefirst 8 weeksThis drugclass are thebackbone ofHR+ diseaseI can give thisagent in highrisk BRCA1/2 mutationfor 1 year

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Based on Oncotype DX, a score of 35 will receive this treatment
  2. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  3. This subtype of breast cancer has the lowest relative 5-year survival rate
  4. This agent can be added to LN+ HER2+ disease given with trastuzumab
  5. 1%
  6. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  7. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  8. This treatment modality is always combined with lumpectomy surgery
  9. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  10. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  11. The only steroidal aromatase inhibitor in its drug class
  12. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  13. Preferred frequency of GnRH agonists
  14. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  15. This agent can cause endometrial cancer, but has bone density protective effect
  16. Preferred regimen for HR+ disease for frail/elderly patients
  17. Duration of time patients will take abemaciclib in early stage disease
  18. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  19. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  20. Patients with HER2+ disease continue targeted therapy for this duration
  21. This should be monitored routinely every 3-4 months while receiving trastuzumab
  22. This agent should be initiated with neratinib for the first 8 weeks
  23. This drug class are the backbone of HR+ disease
  24. I can give this agent in high risk BRCA 1/2 mutation for 1 year